Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF (original) (raw)
Update of IL1 and TNF blockade
Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF
- S Ehlers
- Molecular Infection Biology, Research Centre Borstel, D-23845 Borstel, Germany
- Correspondence to:
Professor S Ehlers, Division of Molecular Infection Biology, Research Centre Borstel, Parkallee 22, D-23845 Borstel, Germany;
sehlers{at}fz-borstel.de
Abstract
Studies in mouse infection models clearly demonstrate tumour necrosis factor (TNF) to be a critical component of both the antibacterially protective and the inflammatory immune response to Mycobacterium tuberculosis. It is therefore not surprising that treatment of patients—for example, those with rheumatoid arthritis—with biological agents interfering with TNF activity have shown an increased risk of reactivating tuberculosis. However, conceivably, TNF targeting biological agents can be developed that because of their particular mode of action and their specific pharmacodynamics may be less likely to have this side effect.
- tumour necrosis factor α
- animal models
- tuberculosis
- HVEM, herpesvirus entry mediator
- KO, knockout
- LT, lymphotoxin
- TNF, tumour necrosis factor
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.